SOUTH SAN FRANCISCO, CA -- 11/03/08 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for
CK-1827452 are scheduled to be presented during a Special Program at the
2008 Scientific Sessions of the American Heart Association which is being
held November 8-12, 2008 at the Ernest N. Morial Convention Center in New
Orleans, La. These data represent an additional interim analysis of
results from Cohorts 1 through 3 and four additional patients from Cohort 4
in an ongoing clinical trial evaluating CK-1827452 in stable heart failure
patients. CK-1827452 is a novel cardiac myosin activator being developed
for the potential treatment of patients with either acutely decompensated
or chronic heart failure.
Oral Presentation at the Scientific Session of the American Heart
Association
"The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic
Function in a Concentration-Dependent Manner in Patients with Stable Heart
Failure" will be presented in a Cardiovascular Seminar (#117) entitled
"Translational Trials and Strategies: First in Man" on Sunday, November 9,
2008, from 5:15 PM - 6:45 PM Central in Rooms 275-277 of Ernest N. Morial
Convention Center. The presentation will be made by John Cleland, MD,
FACC, FRCP, FESC, Professor of Cardiology, Castle Hill Hospital, University
of Hull, United Kingdom.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
cardiovascular disease program is focused to cardiac myosin, a motor
protein essential to cardiac muscle contraction. Cytokinetics' lead
compound from this program, CK-1827452, a novel small molecule cardiac
myosin activator, entered Phase II clinical trials for the treatment of
heart failure in 2007. Under a strategic alliance established in 2006,
Cytokinetics and Amgen Inc. are performing joint research focused on
identifying and characterizing activators of cardiac myosin as back-up and
follow-on potential drug candidates to CK-1827452. Amgen has obtained an
option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is
conducting the Phase I portion of a Phase I/II clinical trial of ispinesib
as monotherapy as a first-line treatment in chemotherapy-naïve patients
with locally advanced or metastatic breast cancer. In addition,
Cytokinetics is conducting the Phase I portion of a Phase I/II trial of
SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an
option for the joint development and commercialization of ispinesib and
SB-743921. GSK-923295, a CENP-E inhibitor, is being developed under the
strategic alliance by GSK; GSK began a Phase I clinical trial with
GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of
a potential drug candidate directed towards skeletal muscle contractility
which may be developed as a potential treatment for skeletal muscle
weakness associated with neuromuscular diseases or other conditions. All of
these drug candidates and potential drug candidates have arisen from
Cytokinetics' research activities and are directed towards the
cytoskeleton. The cytoskeleton is a complex biological infrastructure that
plays a fundamental role within every human cell. Additional information
about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to the planned presentation at the
American Heart Association meeting of results from Cytokinetics' ongoing
clinical trial with CK-1827452 and the potential benefits of Cytokinetics'
drug candidates and potential drug candidates. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to,
potential difficulties or delays in the development, testing, regulatory
approval, production and marketing of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development,
product approval or market acceptance, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics' drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and other
risks related to Cytokinetics' business, investors should consult
Cytokinetics' filings with the Securities and Exchange Commission.
Contact:
Christopher S. Keenan
Director, Investor Relations
(650) 624-3000
